Revised forecast
Fiscal 2026 · Full yearPrevious forecast published 13 February 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Mainly because shipments of the Company's product Episil to China have remained weak. The forecast for cost of product sales has also been revised from ¥220 million to ¥190 million.
| Item | Details |
|---|---|
| Net Sales | 420 Millions of yen → 350 Millions of yen（-16.7%） |
| Fiscal Period Covered | Fiscal 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 13 February 2026 |
| Reason for the revision | Mainly because shipments of the Company's product Episil to China have remained weak. The forecast for cost of product sales has also been revised from ¥220 million to ¥190 million. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The forecast for product sales revenue was revised downward mainly because shipments of Episil to China have remained weak. The amount of revenue from the partial license agreement fee cannot be disclosed under a confidentiality agreement with MAAB.